A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: Findings from a review of randomised controlled trials of rheumatoid arthritis

BMJ (Online)

Volumn 357, Issue , 2017, Pages

  Kirkham, Jamie J ^a   Clarke, Mike ^b   Williamson, Paula R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT;

ANALYTIC METHOD; CLINICAL OUTCOME; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE PLANNING; HUMAN; MATHEMATICAL COMPUTING; MEDICAL INFORMATION; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; BIOASSAY; EVIDENCE BASED MEDICINE; METHODOLOGY; PROCEDURES; PUBLISHING;

ARTHRITIS, RHEUMATOID; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PUBLISHING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RESEARCH DESIGN;

EID: 85019770974     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j2262     Document Type: Review

References (25)

1. Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: Issues to consider. Trials 2012;13:132. doi:10.1186/1745-6215-13-132.
2. Kirkham JJ, Gorst S, Altman DG, et al. Core Outcome Set-STAndards for Reporting: The COS-STAR Statement. PLoS Med 2016;13:e1002148. doi:10.1371/journal.pmed.1002148.
3. OMERACT Initiative. Outcome Measures in Rheumatology www. omeract.org/. Accessed November 7, 2016
4. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38. doi:10.1186/1745-6215-8-38.
5. Boers M, Tugwell P, Felson DT, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl 1994;41:86-9.
6. Kirkham JJ, Boers M, Tugwell P, Clarke M, Williamson PR. Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials 2013;14:324. doi:10.1186/1745-6215-14-324.
7. Gorst SL, Gargon E, Clarke M, Smith V, Williamson PR. Choosing important health outcomes for comparative effectiveness research: An updated review and identification of gaps. PLoS One 2016;11:e0168403. doi:10.1371/journal.pone.0168403.
8. Clarke M, Williamson P. Core outcome sets and trial registries. Trials 2015;16:216. doi:10.1186/s13063-015-0738-6.
9. Felson DT, Anderson JJ, Boers M, et al. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40. doi:10.1002/art.1780360601.
10. US Department of Health and Human Services. Food and Drug Administration: Guidance for Industry Clinical Development Programs for Drugs, Devices, Biological Products for the Treatment of Rheumatoid Arthritis (RA). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071579. pdf. Updated February 1999. Accessed December 9, 2016
11. The European Agency for the Evaluation of Medicinal Products. Unit for the Evaluation of Medicinal Products for Human Use: Guideline on Clinical Investigation of Medicinal Products other than NSAIDs for Treatment of Rheumatoid Arthritis. www.emea.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003439.pdf. Updated December 17, 2003. Accessed December 9, 2016
12. Kirwan JR, Minnock P, Adebajo A, et al. Patient perspective: Fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 2007;34:1174-7.
13. Tugwell P, Idzerda L, Wells GA. Generic quality-of-life assessment in rheumatoid arthritis. Am J Manag Care 2007;13(Suppl 9):S224-36.
14. Viergever RF, Karam G, Reis A, Ghersi D. The quality of registration of clinical trials: Still a problem. PLoS One 2014;9:e84727. doi:10.1371/journal.pone.0084727.
15. Norris SL, Holmer HK, Fu R, Ogden LA, Viswanathan MS, Abou-Setta AM. Clinical trial registries are of minimal use for identifying selective outcome and analysis reporting. Res Synth Methods 2014;5:273-84. doi:10.1002/jrsm.1113.
16. Weston J, Dwan K, Altman D, et al. Feasibility study to examine discrepancy rates in prespecified and reported outcomes in articles submitted to The BMJ. BMJ Open 2016;6:e010075. doi:10.1136/bmjopen-2015-010075.
17. Barnes KL, Kirkham JJ, Clarke M, Williamson PR. Citation analysis: A new approach to assess the uptake of core outcome sets?J Clin Epidemiol 2017;S0895-4356(16)30300-6.
18. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/resources/trends. Accessed November 7, 2016]
19. International Committee of Medical Journal Editors. http://icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. Accessed November 7, 2016
20. Zarin DA, Tse T, Williams RJ, Carr S. Trial Reporting in ClinicalTrials. gov-The Final Rule. N Engl J Med 2016;375:1998-2004. doi:10.1056/NEJMsr1611785.
21. COMET initiative. Core Outcome Measures in Effectiveness Trials. www.comet-initiative.org/. Accessed November 18, 2016
22. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: Guidance for protocols of clinical trials. BMJ 2013;346:e7586. doi:10.1136/bmj.e7586.
23. National Institute for Health Research. (Health Technology Assessment (HTA) Programme). www.nets.nihr.ac.uk/-data/assets/pdf-file/0005/129866/HTA-EoI-Guidance-Notes-V1.15.pdf. Accessed November 18, 2016
24. European Medicines Agency. Guideline on the clinical investigation of medicinal products for the treatment of asthma. www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2015/12/WC500198877.pdf. Accessed November 18, 2016]
25. Clarke M, Williamson P. Core outcome sets and trial registries. Trials 2015;16:216. doi:10.1186/s13063-015-0738-6.